• 1
    Bauer W, Briner U, Doepfner W, Haller R, Huguenin R, Marback P, Petcher TJ. et al. SMS 201–995: a very potent and selective octapeptide analogue of somatostatin with prolonged action. Life Sci 1982; 31: 11331140.
  • 2
    Hwang SJ, Lin HC, Chang CF, Lee FY, Lu CW, Hsia HC, Wang SS. et al. A randomized controlled trial comparing octreotide and vasopressin in the control of acute esophageal variceal bleeding. J Hepatol 1992; 16: 320325.
  • 3
    Sung JJY, Chung SCS, Lai CW, Chan FKL, Leung JWC, Yung MY, Kassianides C. et al. Octreotide infusion or emergency sclero-therapy for variceal haemorrhage. Lancet 1993; 342: 637641.
  • 4
    Silvain C, Carpentier S, Sautereau D, Czernichow B, Mtreau JM, Fort E, Ingrand P. et al. Terlipressin plus transdermal nitro-glycerin vs. octreotide in the control of acute bleeding from esophageal varices: a multicenter randomized trial. Hepatology 1994; 18: 6165.
  • 5
    Cerini R, Lee SS, Hadengue A, Koshy A, Girod C, Lebrec D. Circulatory effects of somatostatin analogue in two conscious rat models of portal hypertension. Gastroenterology 1988; 94: 703708.
  • 6
    Albillos A, Colombato LA, Lee FY, Groszmann RJ. Octreotide ameliorates vasodilatation and Na+ retention in portal hypertensive rats. Gastroenterology 1993; 104: 575579.
  • 7
    Eriksson LS, Brundin T, Söderlund C, Wahren J. Haemodynamic effects of a long-acting somatostatin analogue in patients with liver cirrhosis. Scand J Gastroenterol 1987; 22: 919925.
  • 8
    Pringle SD, McKee RF, Garden OJ, Lorimer AR, Carter DC. The effect of a long-acting somatostatin analogue on portal and systemic haemodynamics in cirrhosis. Aliment Pharmacol Ther 1988; 2: 451459.
  • 9
    McCormick PA, Dick R, Siringo S, Wagstaff D, Chesta J, McLntyre N, Burroughs AK. Octreotide reduces azygos blood flow in cirrhotic patients with portal hypertension. Eur J Gastroenterol Hepatol 1990; 2: 489492.
  • 10
    Lin HC, Tsai YT, Lee FY, Lee SD, Hsia HC, Lin WJ, Lo KJ. Hemodynamic evaluation of octreotide in patients with hepatitis B-related cirrhosis. Gastroenterology 1992; 103: 229234.
  • 11
    McCormick PA, Biagini MR, Dick R, Greenslade L, Chin J, Cardin F, Wagstaff D. et al. Octreotide inhibits the meal-induced increases in the portal venous pressure of cirrhotic patients with portal hypertension: a double-blind, placebo-controlled study. Hepatology 1992; 16: 11801186.
  • 12
    Sarin SK, Groszmann RJ, Mosca PG, Rojkind M, Satdecker MJ, Bhatnagar R, Reuben A. et al. Propranolol ameliorates the development of portal-systemic shunting in a chronic murine schisto-somiasis model of portal hypertension. J Clin Invest 1991; 87: 10321036.
  • 13
    Lin HC, Soubrane O, Cailmail S, Lebrec D. Early chronic administration of propranolol reduces the severity of portal hypertension and portal-systemic shunts in conscious portal vein stenosed rats. J Hepatol 1991; 13: 213219.
  • 14
    Lin HC, Soubrane O, Lebrec D. Prevention of portal hypertension and portosystemic shunts by early chronic administration of clonidine in conscious portal vein-stenosed rats. Hepatology 1991; 14: 325330.
  • 15
    Lee FY, Colombato LA, Albillos A, Groszmann RJ. Administration of Nw-Nitro- L -arginine ameliorates portal systemic shunting in portal-hypertensive rats. Gastroenterology 1993; 105: 14641470.
  • 16
    Lee SS, Girod C, Braillon A, Hadengue A, Lebrec D. Hemodynamic characterization of chronic bile duct-ligated rats: effect of pentobarbital sodium. Am J Physiol 1986; 251: G176G180.
  • 17
    Lee SS, Girod C, Valla D, Geoffroy P, Lebrec D. Effects of pentobarbital sodium anesthesia on splanchnic hemodynamics of normal and portal-hypertensive rats. Am J Physiol 1985; 249: G528G532.
  • 18
    Sikuler E, Buchs AE, Yaari A, Keynan A. Hemodynamic characterization of conscious and ketamine-anesthetized bile duct-ligated rats. Am J Physiol 1991; 260: G161G166.
  • 19
    Sieber CC, Mosca PG, Groszmann RJ. Effect of somatostatin on mesenteric vascular resistance in normal and portal hypertensive rats. Am J Physiol 1992; 262: G274G277.
  • 20
    Colombato LA, Albillos A, Groszmann RJ. Temporal relationship of peripheral vasodilatation, plasma volume expansion and the hyperdynamic circulatory state in portal hypertensive rats. Hepatology 1992; 15: 323328.
  • 21
    Sikuler E, Kravetz D, Groszmann RJ. Evolution of portal hypertension and mechanisms involved in its maintenance in a rat model. Am J Physiol 1985; 248: G618G625.
  • 22
    Pizcueta MP, García-Pagán JC, Fernández M, Casamitjana R, Bosch J, Rodés J. Glucagon hinders the effects of somatostatin on portal hypertension: a study in rats with partial portal vein ligation. Gastroenterology 1991; 101: 17101715.
  • 23
    Pizcueta MP, Casamiyjana R, Bosch J, Rodés J. Decreased systemic vascular sensitivity to norepinephrine in portal hypertensive rats: role of hyperglucagonism. Am J Physiol 1990; 258: G191G195.
  • 24
    Mesh CL, Joh T, Korthuis RJ, Granger DN, Benoit JN. Intestinal vascular sensitivity to vasopressin in portal hypertensive rats. Gastroenterology 1991; 100: 916921.
  • 25
    Sieber CC, Lee FY, Groszmann RJ. Chronic octreotide treatment prevents the in vitro vascular hyporeactivity in portal hypertensive rats. Hepatology 1994; 19: 1241. Abstract.
  • 26
    Brown MR. Somatostatin-28 effects on central nervous system regulation of vasopressin secretion and blood pressure. Neuroen-docrinology 1988; 47: 556562.
  • 27
    Rettig R, Geist R, Sauer U, Rohmeiss P, Unger T. Central effects of somatostatin: pressor response, AVP release, and sympathoin-hibition. Am J Physiol 1989; 257: R588R594.
  • 28
    Bendtsen F, Schifter S, Henriksen JH. Increased circulating cal-citonin gene-related peptide (CGRP) in cirrhosis. J Hepatol 1991; 12: 118123.
  • 29
    Fernández-Rodriguez CM, Prieto J, Quiroga J, Zozoya JM, An-drade A, Núñez M, Sangro B. et al. Plasma levels of substance P in liver cirrhosis: relationship to the activation of vasopressor systems and urinary sodium excretion. Hepatology 1995; 21: 3540.
  • 30
    Nguyen LS, Villablanca AC, Rutledge JC. Substance P increases microvascular permeability via nitric oxide-mediated convective pathways. Am J Physiol 1995; 268: R1060R1068.
  • 31
    Gray DW, Marshall I. Human α-calcitonin gene-related peptide stimulates adenylate cyclase and guanylate cyclase and relaxes rat thoracic aorta by releasing nitric oxide. Br J Pharmacol 1992; 107: 691696.
  • 32
    Schini-Kerth VB, Fisslthaler B, Busse R. CGRP enhances induction of NO synthase in vascular smooth muscle cells via a cAMP-dependent mechanism. Am J Physiol 1994; 267: H2483H2490.
  • 33
    Pizcueta P, Piqué JM, Fernández M, Bosch J, Rodés J, Whittle BJR, Moncada S. Modulation of the hyperdynamic circulation of cirrhotic rats by nitric oxide inhibition. Gastroenterology 1992; 103: 19091915.
  • 34
    Lee FY, Colombato LA, Albillos A, Groszmann RJ. Nw-Nitro- L -arginine administration corrects peripheral vasodilation and systemic capillary hypotension and ameliorates plasma volume expansion and sodium retention in portal hypertensive rats. Hepatology 1993; 17: 8490.
  • 35
    García-Pagán JC, Fernández M, Bernadich C, Pizcueta P, Piqué JM, Bosch J, Rodés J. Effects of continued NO inhibition on portal hypertensive syndrome after portal vein stenosis in rat. Am J Physiol 1994; 267: G984G990.
  • 36
    Geraghty JG, Angerson WJ, Carter DC. Portal venous pressure and portasystemic shunting in experimental portal hypertension. Am J Physiol 1987; 257: G52G57.
  • 37
    Smith-Laing G, Orskov H, Gore MBR, Sherlock S. Hyperglucago-naemia in cirrhosis: relationship to hepatocellular damage. Dia-betologia 1980; 19: 103108.
  • 38
    Benoit JN, Barrowman JA, Harper SL, Kvietys PR, Granger DN. Role of humoral factors in the intestinal hyperemia associated with chronic portal hypertension. Am J Physiol 1984; 247: G486G493.
  • 39
    Pak JM, Lee SS. Glucagon in portal hypertension. J Hepatol 1994; 20: 825832.
  • 40
    Romeo JM, Novo C, Fernández-Cruz A, Lòpez-Novoa JM. Hemodynamic effects of somatostatin in the rat: relationship with plasma glucagon levels. Heart Vessels 1990; 5: 219223.
  • 41
    McCormick PA, Chin J, Greenslade L, Karatapanis S, Dick R, McLntyre N, Burroughs AK. Cardiovascular effects of octreotide in patients with hepatic cirrhosis. Hepatology 1995; 21: 12551260.
  • 42
    Webb SC, Kirikler DM, Hendry WG, Adrian TE, Bloom SR. Elec-trophysiologcal actions of somatostatin on the atrioventricular junction in sinus rhythm and reentry tachycardia. Br Heart J 1986; 56: 236241.
  • 43
    Li Y, Owyang C. Somatostatin inhibits pancreatic enzyme secretion at a central vagal site. Am J Physiol 1993; 265: G251G257.
  • 44
    Jenkins SA, Ellenbogen S, Baxter JN, Critchley M, Grime JS, Shields R. Sandostatin in the long term management of portal hypertension: a preliminary prospective randomized controlled clinical trial. Gut 1991; 32: A328.